Tumor interstitial fluid formation, characterization, and clinical implications

Frontiers in Oncology

Volumn 5, Issue MAY, 2015, Pages

  Wagner, Marek ^a   Wiig, Helge ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Biomarkers; Extracellular matrix; Extracellular space; Interstitial space; Proteomics; Tumor extracellular fluid; Tumor microenvironment

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PEROXIREDOXIN 1; THROMBOSPONDIN 1; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN THIOLESTERASE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; BIOPSY; CYTOTOXIC LYMPHOCYTE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INTERSTITIAL FLUID; METASTASIS; MICRODIALYSIS; NEOPLASM; NONHUMAN; PROTEOMICS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ULTRAFILTRATION;

EID: 84934271859     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00115     Document Type: Review

References (139)

1. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev (1993) 73:1-78.
2. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol (2005) 5:617-28. doi: 10.1038/nri1670
3. Baronzio G, Schwartz L, Kiselevsky M, Guais A, Sanders E, Milanesi G, et al. Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis. Anticancer Res (2012) 32:405-14.
4. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair (2010) 3:12. doi:10.1186/1755-1536-3-12
5. Baronzio G, Parmar G, Baronzio M, Kiselevsky M. Tumor interstitial fluid: proteomic determination as a possible source of biomarkers. Cancer Genomics Proteomics (2014) 11:225-37.
6. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 10:371-8. doi:10.1038/nrc2831
7. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev (2012) 92:1005-60. doi:10.1152/physrev.00037.2011
8. Haslene-Hox H, Tenstad O, Wiig H. Interstitial fluid-a reflection of the tumor cell microenvironment and secretome. Biochim Biophys Acta (2013) 1834:2336-46. doi:10.1016/j.bbapap.2013.01.028
9. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer (2006) 6:392-401. doi:10.1038/nrc1877
10. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 4:839-49. doi:10.1038/nrc1477
11. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature (2001) 411:375-9. doi:10.1038/35077241
12. Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev (2009) 28:177-83. doi:10.1007/s10555-008-9175-2
13. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep (2014) 15:1243-53. doi:10.15252/embr.201439246
14. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res (2014) 12:297-312. doi:10.1158/1541-7786.MCR-13-0535
15. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 196:395-406. doi:10.1083/jcb.201102147
16. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 501:346-54. doi:10.1038/nature12626
17. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
18. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol (2015) 33:445-74. doi:10.1146/annurev-immunol-032414-112043
19. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature (2013) 496:445-55. doi:10.1038/nature12034
20. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep (2014) 6:13. doi:10.12703/P6-13
21. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12:298-306. doi:10.1038/nrc3245
22. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 14:1014-22. doi:10.1038/ni.2703
23. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 179:977-83. doi:10.4049/jimmunol.179.2.977
24. Mahfouz SM, Chevallier M, Grimaud JA. Distribution of the major connective matrix components of the stromal reaction in breast carcinoma. An immunohistochemical study. Cell Mol Biol (1987) 33:453-67.
25. Takeuchi J, Sobue M, Sato E, Shamoto M, Miura K. Variation in glycosaminoglycan components of breast tumors. Cancer Res (1976) 36:2133-9.
26. Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol (1991) 138:1437-50.
27. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev (1996) 76:69-125.
28. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 5:1041-56.
29. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 94:715-25. doi:10.1016/S0092-8674(00)81731-6
30. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med (1991) 174:1275-8. doi:10.1084/jem.174.5.1275
31. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219:983-5. doi:10.1126/science.6823562
32. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315:1650-9. doi:10.1056/NEJM198612253152606
33. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436-44. doi:10.1038/nature07205
34. Christiansen A, Detmar M. Lymphangiogenesis and cancer. Genes Cancer (2011) 2:1146-58. doi:10.1177/1947601911423028
35. Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol (2014) 15:771-85. doi:10.1038/nrm3902
36. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 15:786-801. doi:10.1038/nrm3904
37. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol (1896) 19:312-26. doi:10.1113/jphysiol.1896.sp000596
38. Levick JR, Michel CC. Microvascular fluid exchange and the revised starling principle. Cardiovasc Res (2010) 87:198-210. doi:10.1093/cvr/cvq062
39. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 101:937-49. doi:10.1002/jcb.21187
40. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer (2004) 4:806-13. doi:10.1038/nrc1456
41. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 91:1071-121. doi:10.1152/physrev.00038.2010
42. Wiig H. Evaluation of methodologies for measurement of interstitial fluid pressure (Pi): physiological implications of recent Pi data. Crit Rev Biomed Eng (1990) 18:27-54.
43. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21:418-29. doi:10.1016/j.ccr.2012.01.007
44. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release (2015) 201:78-89. doi:10.1016/j.jconrel.2014.12.018
45. Ariffin AB, Forde PF, Jahangeer S, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res (2014) 74:2655-62. doi:10.1158/0008-5472.CAN-13-3696
46. Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol (2013) 3:211. doi:10.3389/fonc.2013.00211
47. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 146:1029-39.
48. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol (2003) 163:1801-15. doi:10.1016/S0002-9440(10)63540-7
49. Wiig H, Tveit E, Hultborn R, Reed RK, Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest (1982) 42:159-64. doi:10.3109/00365518209168068
50. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res (2000) 60:4251-5.
51. Wiig H, Aukland K, Tenstad O. Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Heart Circ Physiol (2003) 284:H416-24. doi:10.1152/ajpheart.00327.2002
52. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 60:4324-7.
53. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 296:1883-6. doi:10.1126/science.1071420
54. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature (2004) 427:695. doi:10.1038/427695a
55. Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2015) 25:198-213. doi:10.1016/j.tcb.2014.11.006
56. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature (2005) 438:946-53. doi:10.1038/nature04480
57. Thiele W, Sleeman JP. Tumor-induced lymphangiogenesis: a target for cancer therapy? J Biotechnol (2006) 124:224-41. doi:10.1016/j.jbiotec.2006.01.007
58. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med (2001) 7:186-91. doi:10.1038/84635
59. Xu BJ, Yan W, Jovanovic B, Shaw AK, An QA, Eng J, et al. Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo. Cancer Microenviron (2010) 4:61-71. doi:10.1007/s12307-010-0046-3
60. Wiig H. Cornea fluid dynamics. I: measurement of hydrostatic and colloid osmotic pressure in rabbits. Exp Eye Res (1989) 49:1015-30. doi:10.1016/S0014-4835(89)80023-5
61. Aukland K. Distribution volumes and macromolecular mobility in rat tail tendon interstitium. Am J Physiol (1991) 260:H409-19.
62. Choi J, Credit K, Henderson K, Deverkadra R, He Z, Wiig H, et al. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin Cancer Res (2006) 12:1906-12. doi:10.1158/1078-0432.CCR-05-2141
63. Salnikov AV, Heldin NE, Stuhr LB, Wiig H, Gerber H, Reed RK, et al. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer (2006) 119:2795-802. doi:10.1002/ijc.22217
64. Haslene-Hox H, Oveland E, Berg KC, Kolmannskog O, Woie K, Salvesen HB, et al. A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue. PLoS One (2011) 6:e19217. doi:10.1371/journal.pone.0019217
65. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics (2004) 3:327-44. doi:10.1074/mcp.M400009-MCP200
66. Leegsma-Vogt G, Janle E, Ash SR, Venema K, Korf J. Utilization of in vivo ultrafiltration in biomedical research and clinical applications. Life Sci (2003) 73:2005-18. doi:10.1016/S0024-3205(03)00569-1
67. Schneiderheinze JM, Hogan BL. Selective in vivo and in vitro sampling of proteins using miniature ultrafiltration sampling probes. Anal Chem (1996) 68:3758-62. doi:10.1021/ac960309u
68. Huang CM, Ananthaswamy HN, Barnes S, Ma Y, Kawai M, Elmets CA. Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics (2006) 6:6107-16. doi:10.1002/pmic.200600287
69. Yang S, Huang CM. Recent advances in protein profiling of tissues and tissue fluids. Expert Rev Proteomics (2007) 4:515-29. doi:10.1586/14789450.4.4.515
70. Dabrosin C. Microdialysis-an in vivo technique for studies of growth factors in breast cancer. Front Biosci (2005) 10:1329-35. doi:10.2741/1622
71. Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, et al. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 6:65-74. doi:10.1215/S1152851703000103
72. Brunner M, Muller M. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur J Clin Pharmacol (2002) 58:227-34. doi:10.1007/s00228-002-0475-0
73. Liu L, Zhang X, Lou Y, Rao Y, Zhang X. Cerebral microdialysis in glioma studies, from theory to application. J Pharm Biomed Anal (2014) 96:77-89. doi:10.1016/j.jpba.2014.03.026
74. Blakeley J, Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol (2010) 6:1477-91. doi:10.1517/17425255.2010.523420
75. Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J (2005) 7:E659-67. doi:10.1208/aapsj070366
76. Ao X, Stenken JA. Microdialysis sampling of cytokines. Methods (2006) 38:331-41. doi:10.1016/j.ymeth.2005.11.012
77. Clough GF. Microdialysis of large molecules. AAPS J (2005) 7:E686-92. doi:10.1208/aapsj070369
78. Hersini KJ, Melgaard L, Gazerani P, Petersen LJ. Microdialysis of inflammatory mediators in the skin: a review. Acta Derm Venereol (2014) 94:501-11. doi:10.2340/00015555-1878
79. Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol (2009) 182:371-8. doi:10.4049/jimmunol.182.1.371
80. Wibom C, Surowiec I, Moren L, Bergstrom P, Johansson M, Antti H, et al. Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res (2010) 9:2909-19. doi:10.1021/pr901088r
81. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Res (1964) 24:780-98.
82. Jain RK, Shah SA, Finney PL. Continuous noninvasive monitoring of pH and temperature in rat walker 256 carcinoma during normoglycemia and hyperglycemia. J Natl Cancer Inst (1984) 73:429-36.
83. Grahovac J, Wells A. Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion. Lab Invest (2014) 94:31-40. doi:10.1038/labinvest.2013.132
84. Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Exp Dermatol (2014) 23:457-63. doi:10.1111/exd.12435
85. Monboisse JC, Oudart JB, Ramont L, Brassart-Pasco S, Maquart FX. Matrikines from basement membrane collagens: a new anti-cancer strategy. Biochim Biophys Acta (2014) 1840:2589-98. doi:10.1016/j.bbagen.2013.12.029
86. Voloshin T, Fremder E, Shaked Y. Small but mighty: microparticles as mediators of tumor progression. Cancer Microenviron (2014) 7:11-21. doi:10.1007/s12307-014-0144-8
87. Andaloussi SE, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov (2013) 12:347-57. doi:10.1038/nrd3978
88. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol (2014) 30:255-89. doi:10.1146/annurev-cellbio-101512-122326
89. Antonyak MA, Cerione RA. Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol (2014) 1165:147-73. doi:10.1007/978-1-4939-0856-1_11
90. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res (2010) 107:1047-57. doi:10.1161/CIRCRESAHA.110.226456
91. Morel O, Morel N, Jesel L, Freyssinet JM, Toti F. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol (2011) 33:469-86. doi:10.1007/s00281-010-0239-3
92. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev (2012) 26:1287-99. doi:10.1101/gad.192351.112
93. D'Asti E, Garnier D, Lee TH, Montermini L, Meehan B, Rak J. Oncogenic extracellular vesicles in brain tumor progression. Front Physiol (2012) 3:294. doi:10.3389/fphys.2012.00294
94. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res (2014) 114:345-53. doi:10.1161/CIRCRESAHA.113.300858
95. Julich H, Willms A, Lukacs-Kornek V, Kornek M. Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol (2014) 5:413. doi:10.3389/fimmu.2014.00413
96. Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med (2012) 18:1835-40. doi:10.1038/nm.2994
97. Iversen PO, Wiig H. Tumor necrosis factor alpha and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin Cancer Res (2005) 11:6793-9. doi:10.1158/1078-0432.CCR-05-1033
98. Haslene-Hox H, Madani A, Berg KCG, Woie K, Salvesen HB, Wiig H, et al. Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood. Biochim Biophys Acta Clin (2014) 2:18-23. doi:10.1016/j.bbacli.2014.08.002
99. Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer (2012) 12:210-9. doi:10.1038/nrc3186
100. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell (2007) 11:526-38. doi:10.1016/j.ccr.2007.04.020
101. Sagstad SJ, Oveland E, Karlsen TV, Haslene-Hox H, Tenstad O, Wiig H. Age-related changes in rat dermal extracellular matrix composition affect the distribution of plasma proteins as a function of size and charge. Am J Physiol Heart Circ Physiol (2015) 308:H29-38. doi:10.1152/ajpheart.00545.2014
102. Haslene-Hox H, Oveland E, Woie K, Salvesen HB, Tenstad O, Wiig H. Distribution volumes of macromolecules in human ovarian and endometrial cancers-effects of extracellular matrix structure. Am J Physiol Heart Circ Physiol (2015) 308:H18-28. doi:10.1152/ajpheart.00672.2014
103. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 1:1-48.
104. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 24:971-83. doi:10.1038/nbt1235
105. Veenstra TD. Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 847:3-11. doi:10.1016/j.jchromb.2006.09.004
106. Kondo T. Inconvenient truth: cancer biomarker development by using proteomics. Biochim Biophys Acta (2014) 1844:861-5. doi:10.1016/j.bbapap.2013.07.009
107. Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR, et al. Tumor interstitial fluid-a treasure trove of cancer biomarkers. Biochim Biophys Acta (2013) 1834:2259-70. doi:10.1016/j.bbapap.2013.01.013
108. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer (2002) 95:1886-93. doi:10.1002/cncr.10917
109. Simpson RJ, Bernhard OK, Greening DW, Moritz RL. Proteomics-driven cancer biomarker discovery: looking to the future. Curr Opin Chem Biol (2008) 12:72-7. doi:10.1016/j.cbpa.2008.02.010
110. Teng PN, Bateman NW, Hood BL, Conrads TP. Advances in proximal fluid proteomics for disease biomarker discovery. J Proteome Res (2010) 9:6091-100. doi:10.1021/pr100904q
111. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2006) 5:157-71. doi:10.1074/mcp.M500178-MCP200
112. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med (2008) 6:52. doi:10.1186/1479-5876-6-52
113. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics (2010) 73:2291-305. doi:10.1016/j.jprot.2010.07.001
114. Karagiannis GS, Pavlou MP, Diamandis EP. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol (2010) 4:496-510. doi:10.1016/j.molonc.2010.09.001
115. Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics (2012) 12:722-35. doi:10.1002/pmic.201100346
116. Sun W, Ma J, Wu S, Yang D, Yan Y, Liu K, et al. Characterization of the liver tissue interstitial fluid (TIF) proteome indicates potential for application in liver disease biomarker discovery. J Proteome Res (2010) 9:1020-31. doi:10.1021/pr9009172
117. Hardt M, Lam DK, Dolan JC, Schmidt BL. Surveying proteolytic processes in human cancer microenvironments by microdialysis and activity-based mass spectrometry. Proteomics Clin Appl (2011) 5:636-43. doi:10.1002/prca.201100015
118. Stone MD, Odland RM, McGowan T, Onsongo G, Tang C, Rhodus NL, et al. Novel in situ collection of tumor interstitial fluid from a head and neck squamous carcinoma reveals a unique proteome with diagnostic potential. Clin Proteomics (2010) 6:75-82. doi:10.1007/s12014-010-9050-3
119. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, et al. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol (2010) 4:65-89. doi:10.1016/j.molonc.2009.11.003
120. Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP, Conrads TP. Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One (2011) 6:e25056. doi:10.1371/journal.pone.0025056
121. Raso C, Cosentino C, Gaspari M, Malara N, Han X, McClatchy D, et al. Characterization of breast cancer interstitial fluids by TmT labeling, LTQ-orbitrap velos mass spectrometry, and pathway analysis. J Proteome Res (2012) 11:3199-210. doi:10.1021/pr2012347
122. Li S, Wang R, Zhang M, Wang L, Cheng S. Proteomic analysis of non-small cell lung cancer tissue interstitial fluids. World J Surg Oncol (2013) 11:173. doi:10.1186/1477-7819-11-173
123. Shi HJ, Stubbs R, Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis (2009) 30:2442-53. doi:10.1002/elps.200800767
124. Haslene-Hox H, Oveland E, Woie K, Salvesen HB, Wiig H, Tenstad O. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. Biochim Biophys Acta (2013) 1834:2347-59. doi:10.1016/j.bbapap.2013.05.011
125. Raimondo F, Morosi L, Chinello C, Magni F, Pitto M. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics (2011) 11:709-20. doi:10.1002/pmic.201000422
126. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics (2009) 6:267-83. doi:10.1586/epr.09.17
127. Pieper R, Gatlin CL, Makusky AJ, Russo PS, Schatz CR, Miller SS, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics (2003) 3:1345-64. doi:10.1002/pmic.200300449
128. Wiig H, Keskin D, Kalluri R. Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix Biol (2010) 29:645-56. doi:10.1016/j.matbio.2010.08.001
129. Gullino PM, Grantham FH, Smith SH, Haggerty AC. Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst (1965) 34:857-69.
130. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 8:1284-91.
131. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 3:177-82. doi:10.1038/nm0297-177
132. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res (1999) 59:4525-8.
133. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 26:225-39. doi:10.1007/s10555-007-9055-1
134. Fijneman RJ, de Wit M, Pourghiasian M, Piersma SR, Pham TV, Warmoes MO, et al. Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. Clin Cancer Res (2012) 18:2613-24. doi:10.1158/1078-0432.CCR-11-1937
135. Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, et al. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res (2011) 10:4715-24. doi:10.1021/pr200519q
136. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. J Proteome Res (2011) 10:1333-42. doi:10.1021/pr101074p
137. Cortesi L, Rossi E, Della Casa L, Barchetti A, Nicoli A, Piana S, et al. Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis (2011) 32:1992-2003. doi:10.1002/elps.201000654
138. Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, et al. Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics (2010) 9:1873-84. doi:10.1074/mcp.M110.000802
139. Turtoi A, Dumont B, Greffe Y, Blomme A, Mazzucchelli G, Delvenne P, et al. Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues. J Proteome Res (2011) 10:3160-82. doi:10.1021/pr200212r